BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng L, Xia Z, Bian X, Li G, Hu J, Cao Y, Wang Q, Qian X. Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. Onco Targets Ther 2015;8:3185-92. [PMID: 26586952 DOI: 10.2147/OTT.S82453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Rashid MM, Lee H, Jung BH. Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics. Sci Rep 2020;10:17523. [PMID: 33067464 DOI: 10.1038/s41598-020-73721-w] [Reference Citation Analysis]
2 Lamanuzzi A, Saltarella I, Desantis V, Frassanito MA, Leone P, Racanelli V, Nico B, Ribatti D, Ditonno P, Prete M, Solimando AG, Dammacco F, Vacca A, Ria R. Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma. Oncotarget 2018;9:20563-77. [PMID: 29755672 DOI: 10.18632/oncotarget.25003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
3 Kong L, Zhang Q, Mao J, Cheng L, Shi X, Yu L, Hu J, Yang M, Li L, Liu B, Qian X. A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer. J Gastrointest Oncol 2021;12:1625-42. [PMID: 34532116 DOI: 10.21037/jgo-21-467] [Reference Citation Analysis]